This work was supported by the National Natural Science Foundation of China (NSFC 81672547, 81402110, and 81272820); Science and Technology Support Program of Sichuan Province (2015SZ0142); and the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University.
Even in the era of novel targeted agents, switching to a second-line nonsteroidal antiandrogen (NSAA) is still widely used in treating metastatic castration-resistant prostate cancer (mCRPC), especially in undevel...
The prognostic significance of initial prostate-specific antigen (PSA) level for metastatic prostate cancer remains uncertain. We investigated the differences in prognosis and response to hormonal therapies of metas...
The aim of the present study was to determine whether oncologic outcomes and adverse events associated with active on/off intermittent antiandrogen monotherapy (daily bicalutamide, 50 mg per day) are comparable with...